Helicobacter pylori Vaccine: Mechanism of Pathogenesis, Immune Evasion and Analysis of Vaccine Types
Open Access
Abstract
Helicobacter pylori (H. pylori) is a gram-negative, spiral-shaped bacterium that colonizes the human gastric mucosa, leading to various gastric diseases. H. pylori infection has become a pressing public health issue that affects more than 50% of the human population worldwide, almost 40 years after its discovery. Traditional treatments, based on the use of bismuth-based triple and quadruple therapies, are effective while facing a series of problems, such as difficulty in patient compliance, the rise of antibiotic resistance, and possible recurrence of infection. Therefore, the development of an efficacious vaccine against H. pylori would be extremely urgent. This review mainly elaborates on the pathogenic mechanism and immune evasion mechanism of H. pylori, as well as various strategies adopted in vaccine development, including whole-cell vaccines, subunit vaccines, DNA vaccines, and live vector vaccines. Animal studies and clinical trials demonstrate that H. pylori vaccines significantly reduce bacterial load and provide cellular immunity over some time. Multiple studies have clarified the advantages and limitations of each candidate vaccine. Although the development of H. pylori vaccines provides benefits to reduce the global burden, there are still significant challenges to developing vaccines in safety, efficacy, and availability. Overcoming these challenges, along with the advancement of vaccine technology, can better prevent and treat H. pylori infection.Keywords
Funding Information
- First Hospital of Shanxi Medical University (SYYYRC-2022001, SYYYRC-2022002)
This publication has 100 references indexed in Scilit:
- Long-term evaluation of Helicobacter pylori screening in school health checkups: an 11-year study in JapanJournal of Gastroenterology, 2025
- Nanomaterials in gastric cancer: pioneering precision medicine for diagnosis, therapy, and preventionMedical Oncology, 2025
- Helicobacter pylori CagA elevates FTO to induce gastric cancer progression via a “hit‐and‐run” paradigmCancer Communications, 2025
- Large‐scale cluster randomised trial reveals effectiveness of Helicobacter pylori eradication for gastric cancer preventionClinical and Translational Medicine, 2025
- Oral Live-Carrier Vaccine of Recombinant Lactococcus lactis Inducing Prophylactic Protective Immunity Against Helicobacter pylori InfectionProbiotics and Antimicrobial Proteins, 2024
- Chitosan-LeoA-DNA Nanoparticles Promoted the Efficacy of Novel LeoA-DNA Vaccination on Mice Against Helicobacter pyloriCurrent Microbiology, 2024
- An M cell-targeting recombinant L. lactis vaccine against four H. pylori adhesinsApplied Microbiology and Biotechnology, 2024
- Sustained exposure to Helicobacter pylori induces immune tolerance by desensitizing TLR6Gastric Cancer, 2024
- Synthetic Self‐Adjuvanted Lipopeptide Vaccines Conferred Protection against Helicobacter pylori InfectionAdvanced Healthcare Materials, 2023
- Working group report on schistosomes, liver flukes and Helicobacter pylori. Meeting held at IARC, LYON, 7–14 june 1994International Journal of Cancer, 1995